Want to see HK:2617 full AI Analyst Report?
TransThera Sciences (Nanjing). Inc. (2617) Ratios
TransThera Sciences (Nanjing). Inc. Ratios
HK:2617's free cash flow for Q2 2026 was $0.00. For the 2026 fiscal year, HK:2617's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.87 | 5.66 | 8.24 | 11.97 | 3.09 |
| Quick Ratio | 3.87 | 5.66 | 8.24 | 11.97 | 3.09 |
| Cash Ratio | 3.21 | 5.51 | 4.84 | 10.14 | 0.74 |
| Solvency Ratio | -2.25 | -2.56 | -3.27 | -2.32 | -0.13 |
| Operating Cash Flow Ratio | -1.96 | -2.62 | -3.11 | -2.20 | -0.63 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -0.77 |
| Net Current Asset Value | $ 371.32M | $ 480.68M | $ 741.69M | $ 1.21B | $ -254.25M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.00 | 1.42 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.01 | 0.00 | -2.10 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.01 | 0.00 | 1.91 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 2.37 |
| Financial Leverage Ratio | 1.31 | 1.20 | 1.13 | 1.09 | -1.47 |
| Debt Service Coverage Ratio | -2403.44 | -1333.19 | -1677.12 | -1.88 | -0.37 |
| Interest Coverage Ratio | -2480.84 | -1426.27 | -1542.42 | -1725.64 | -1.16 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Interest Debt Per Share | 0.00 | 0.01 | 13.26 | 8.96 | 1.33 |
| Net Debt to EBITDA | 1.42 | 2.11 | 1.18 | 3203.71 | -10.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 109.94% | 100.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | -35609.58% | -251850.22% | -71.01% |
| EBITDA Margin | 0.00% | 0.00% | -35269.32% | -246958.07% | -63.58% |
| Operating Profit Margin | 0.00% | 0.00% | -32436.64% | -227086102.37% | -71.01% |
| Pretax Profit Margin | 0.00% | 0.00% | -29076.57% | -183145811.92% | -120.61% |
| Net Profit Margin | 0.00% | 0.00% | -29119.32% | -183179430.48% | -130.69% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -29119.32% | -183145811.92% | -130.69% |
| Net Income Per EBT | 100.00% | 100.00% | 100.15% | 100.02% | 108.36% |
| EBT Per EBIT | 98.59% | 95.79% | 89.64% | 80.65% | 169.84% |
| Return on Assets (ROA) | -54.22% | -43.62% | -38.79% | -19.10% | -23.40% |
| Return on Equity (ROE) | -71.08% | -52.30% | -43.94% | -20.81% | 34.50% |
| Return on Capital Employed (ROCE) | -72.09% | -54.48% | -48.86% | -25.78% | -18.29% |
| Return on Invested Capital (ROIC) | -71.81% | -54.15% | -48.65% | -25.71% | -13.46% |
| Return on Tangible Assets | -55.77% | -44.74% | -39.52% | -19.11% | -23.41% |
| Earnings Yield | -0.74% | -3.13% | -4237.30% | -3440.83% | -1.03% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 1.75 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.07 | 0.00 | 3.20 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 208.66 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 208.66 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 208.66 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.65 | -0.68 | -837.24 | -671.33 | -0.17 |
| Free Cash Flow Per Share | -0.65 | -0.69 | -868.16 | -677.05 | -0.19 |
| Dividend Paid and CapEx Coverage Ratio | -1545.80 | -350.82 | -27.08 | -117.33 | -6.71 |
| Capital Expenditure Coverage Ratio | -1545.80 | -350.82 | -27.08 | -117.33 | -6.71 |
| Operating Cash Flow Coverage Ratio | -154.02 | -62.06 | -66.43 | -79.47 | -0.14 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -270.21 | -1722334.81 | -1.08 |
| Free Cash Flow Yield | -0.63% | -3.10% | -4077.13% | -3262.80% | -0.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -135.79 | -31.90 | -0.02 | -0.03 | -97.22 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 6.87 | 53236.92 | 127.05 |
| Price-to-Book (P/B) Ratio | 96.58 | 16.68 | 0.01 | 0.01 | -33.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -158.52 | -32.21 | -0.02 | -0.03 | -102.42 |
| Price-to-Operating Cash Flow Ratio | -158.63 | -32.30 | -0.03 | -0.03 | -117.68 |
| Price-to-Earnings Growth (PEG) Ratio | -13.39 | 0.32 | -0.00 | 0.00 | 3.40 |
| Enterprise Value Multiple | -136.86 | -30.58 | 1.16 | 3182.15 | -210.32 |
| Enterprise Value | 39.80B | 8.19B | -483.70M | -1.10B | 8.26B |
| EV to EBITDA | -136.86 | -30.58 | 1.16 | 3182.15 | -210.32 |
| EV to Sales | 0.00 | 0.00 | -409.30 | -7858578.44 | 133.73 |
| EV to Free Cash Flow | -156.89 | -30.13 | 1.46 | 4.52 | -107.81 |
| EV to Operating Cash Flow | -156.99 | -30.22 | 1.51 | 4.56 | -123.87 |
| Tangible Book Value Per Share | 1.03 | 1.28 | 2010.50 | 3427.52 | -0.59 |
| Shareholders’ Equity Per Share | 1.07 | 1.32 | 2053.42 | 3430.65 | -0.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.08 |
| Revenue Per Share | 0.00 | 0.00 | 3.10 | 0.00 | 0.16 |
| Net Income Per Share | -0.76 | -0.69 | -902.26 | -713.99 | -0.20 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.08 |
| Interest Burden | 1.00 | 1.00 | 0.82 | 727.20 | 1.70 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.32 | 2116.62 | 1.24 |
| SG&A to Revenue | 0.00 | 0.00 | 0.04 | 402.67 | 0.40 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 12.51 | 106190.13 | 0.00 |
| Income Quality | 0.86 | 0.99 | 0.93 | 0.85 | 0.83 |
Currency in CNY